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STUDY QUESTION: Can consensus definitions for the core outcome set for infertility be identified in order to recommend a standard-
ized approach to reporting?
SUMMARY ANSWER: Consensus definitions for individual core outcomes, contextual statements and a standardized reporting table
have been developed.
WHAT IS KNOWN ALREADY: Different definitions exist for individual core outcomes for infertility. This variation increases the oppor-
tunities for researchers to engage with selective outcome reporting, which undermines secondary research and compromises clinical prac-
tice guideline development.
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STUDY DESIGN, SIZE, DURATION: Potential definitions were identified by a systematic review of definition development initiatives
and clinical practice guidelines and by reviewing Cochrane Gynaecology and Fertility Group guidelines. These definitions were discussed in
a face-to-face consensus development meeting, which agreed consensus definitions. A standardized approach to reporting was also devel-
oped as part of the process.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers and people with fertility problems
were brought together in an open and transparent process using formal consensus development methods.
MAIN RESULTS AND THE ROLE OF CHANCE: Forty-four potential definitions were inventoried across four definition development
initiatives, including the Harbin Consensus Conference Workshop Group and International Committee for Monitoring Assisted
Reproductive Technologies, 12 clinical practice guidelines and Cochrane Gynaecology and Fertility Group guidelines. Twenty-seven partici-
pants, from 11 countries, contributed to the consensus development meeting. Consensus definitions were successfully developed for all
core outcomes. Specific recommendations were made to improve reporting.
LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods, which have inherent limitations. There was
limited representation from low- and middle-income countries.
WIDER IMPLICATIONS OF THE FINDINGS: A minimum data set should assist researchers in populating protocols, case report forms
and other data collection tools. The generic reporting table should provide clear guidance to researchers and improve the reporting of their
results within journal publications and conference presentations. Research funding bodies, the Standard Protocol Items: Recommendations
for Interventional Trials statement, and over 80 specialty journals have committed to implementing this core outcome set.
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Introduction
Randomized controlled trials (RCTs) evaluating potential treatments
for infertility have reported many different outcomes (Wilkinson et al.,
2019a). Such variation contributes to challenges in comparing, con-
trasting and combining individual trials, limiting the usefulness of re-
search to inform clinical practice (Duffy et al., 2019b). The
development, dissemination and implementation of a minimum data
set, known as a core outcome set, will help to standardize outcome
selection, collection and reporting across future infertility research.
A core outcome set for infertility (Fig. 1) has been developed (Duffy
et al., 2020a). However, there are inconsistencies in how individual
core outcomes are currently defined by fertility trials. For example,
definitions of live birth include a viable fetus after 24 weeks of gesta-
tion, pregnancy continuation beyond 28 weeks of gestation and deliv-
ery of a living baby (Wilkinson et al., 2016). Such variation makes it
possible for researchers to selectively report their results based on sta-
tistical significance. For example, researchers can undertake multiple
statistical analyses at different gestational thresholds for live birth and
selectively report the most favorable result.
There are unique challenges when reporting the results of infertility
research because of the multistage nature of the treatment, particularly
in the context of IVF (Wilkinson et al., 2016). Multiple clinical and pro-
cedural events can occur during treatment. These events can be
reported in subgroups containing only those patients who reach a cer-
tain milestone, for example, oocyte retrieval, embryo transfer and
 Viable intrauterine pregnancy confirmed by ultrasound. Reporting
 singleton pregnancy, twin pregnancy, and higher multiple pregnancy. 
 Pregnancy loss. Reporting ectopic pregnancy, miscarriage, stillbirth,
 and termination of pregnancy 
 Live birth. 
 Gestational age at delivery. 
 Birthweight. 
 Neonatal mortality. 
 Major congenital anomaly.
*  When applicable → time to pregnancy leading to live birth.
Figure 1. A core outcome set for future infertility research.




































































































implantation. When reporting individual core outcomes, there could
be many denominators available. This enables researchers to under-
take multiple analyses using different denominators and selectively re-
port results.
The variation in definitions and poor reporting practices makes com-
paring and combining individual RCTs challenging. When these practi-
ces are common, it is likely the benefits of fertility treatments are being
overestimated and the harms of treatments are being underestimated
(Duffy et al., 2019b). This undermines secondary research, including in-
dividual patient data (IPD) meta-analysis and network meta-analysis,
and compromises clinical practice guideline development. Standardizing
definitions and improving reporting for individual core outcomes cre-
ates an opportunity to develop additional consistency in future infertil-
ity trials and ensure that secondary research can be undertaken
prospectively, efficiently and harmoniously (Duffy et al., 2017a).
No guidelines have established recommendations regarding the de-
velopment of consensus definitions and reporting guidelines for individ-
ual core outcomes (Williamson et al., 2017). Outside the context of
core outcome set development, the Harbin Consensus Conference
Workshop has developed a standardized definition for live birth (The
Harbin Consensus Conference Workshop Group, 2014) and the
International Committee for Monitoring Assisted Reproductive
Technologies (ICMART) has standardized definitions related to infertil-
ity and ART (Zegers-Hochschild et al., 2017).
Motivated by the desire to maximize the potential of infertility re-
search to inform clinical practice, an international collaboration coordi-
nated by the Cochrane Gynaecology and Fertility Group has brought
healthcare professionals, researchers and people with infertility to-
gether to standardize definitions for the core outcome set for
infertility.
Materials and methods
The study was prospectively registered with the Core Outcome
Measures in Effectiveness Trials (COMET) initiative, registration
number 1023. An international steering group, including healthcare
professionals, researchers and people with fertility problems, was
established to provide a perspective to inform key methodological
decisions.
The important work of the Harbin Consensus Conference Working
Group and ICMART is complementary to this study.
A protocol describing the study’s consensus methods has been pub-
lished (Duffy et al., 2018). The protocol was developed with reference
to the COMET initiative handbook (Williamson et al., 2017). The pro-
tocol was also informed by a systematic review of registered, progress-
ing and completed core outcome sets relevant to women’s and
newborn health (Duffy et al., 2017b) and the experiences of steering
group members involved in other core outcome set development
studies (Hirsch et al., 2016; Khalil et al., 2017; Webbe et al., 2017;
Whitehouse et al., 2017; Khalil et al., 2019).
Potential definitions for individual core outcomes were extracted
from definition development initiatives and national and international
clinical practice guidelines and by reviewing the Cochrane Gynaecology
and Fertility Group’s standardized guidance for infertility reviews. A
systematic review was undertaken searching the COMET initiative reg-
ister to identify definition development initiatives relevant to infertility
research, from inception to October 2018. Clinical practice guidelines
relevant to infertility were identified by searching bibliographical data-
bases, including Embase, MEDLINE and PubMed, from inception to
October 2018. The Cochrane Gynaecology and Fertility Group pro-
vided access to their editorial policy, which describes their standard-
ized approach to the selection of outcomes and definitions across
Cochrane reviews evaluating potential fertility treatments. Using a
pilot-tested and standardized data extraction form, definitions were
extracted verbatim from all sources. An inventory was developed by
organizing potential definitions within an organizational framework
(Supplementary Fig. S1). Steering group members with expertise in
statistics and research methodology prepared discussion points related
to the analysis and reporting of the core outcome set. The inventory
and discussion points were discussed during a face-to-face consensus
development meeting held in Auckland, New Zealand.
The consensus development conference is a formal consensus de-
velopment method developed by the US National Institutes of Health
and has been used to reach consensus for definitions, clinical practice
recommendations and professional competencies (Ferguson, 1996).
The consensus method was developed to include aspects of judicial
decision-making, scientific conferences and the town hall meeting.
Participants hear evidence on which they will later deliberate and are
able to ask questions as the evidence is presented. The chairperson is
responsible for directing the discussion. The group discussion follows
an informal format.
Healthcare professionals, researchers and people with fertility prob-
lems who had participated in the Delphi survey, which informed the
development of the core outcome set for infertility, were invited to
participate (Duffy et al., 2020a). The study aimed to recruit between
10 and 15 participants, as this number has yielded sufficient results and
assured validity in other studies (Murphy et al., 1998).
Before starting the meeting, participants provided demographic
details. The group discussion followed an informal format with the
chairperson providing direction. Each core outcome was discussed in
turn. Potential definitions were displayed within the definition hierar-
chy. Each participant was asked to contribute their opinions.
Participants were encouraged to suggest other potential definitions or
reformulate individual definitions to improve clarity or comprehension.
Although the group was encouraged to reach consensus, members
were able to express minority or alternative views when consensus
could not be achieved. Participants were encouraged to agree contex-
tual statements to highlight important methodological issues which
would need to be considered when reporting individual core
outcomes. Participants also developed consensus guidance regarding
statistical analysis and a reporting table.
Results
Potential definitions were inventoried across four definition develop-
ment initiatives, including the Brighton Collaboration (Chen et al.,
2016), Harbin Consensus Conference Workshop Group, ICMART
and World Health Organization (WHO) (World Health Organization,
2018), 12 clinical practice guidelines (American Urological Association,
2010a,b,c; Jarvi et al., 2010; Kroon et al., 2011; Koch et al., 2012;
National Institute for Health and Care Excellence, 2013; Loh et al.,
2014; Carranza-Mamane et al., 2015; Practice Committee of the




































































































American Society for Reproductive Medicine; 2017a,b; Jungwirth et al.,
2018), and the standardized methods advocated by the Cochrane
Gynaecology and Fertility Group for the preparation of systematic
reviews evaluating potential fertility treatments.
Forty-four potential definitions were discussed during the consensus
development meeting. Twenty-seven participants, including 14 health-
care professionals, 7 researchers and 6 people with fertility problems,
from 11 countries, participated in the consensus development meeting
(Table I).
Live birth
When considering live birth, participants noted the Improving the
reporting of clinical trials of infertility treatments (IMPRINT) statement
recommended a gestational age threshold of 20 completed weeks.
This statement was specifically developed to improve outcome report-
ing in infertility trials by modifying the Consolidated Standards of
Reporting Trials (CONSORT) statement (Moher et al., 2010). Given
this context, participants agreed the IMPRINT gestational threshold
should be recommended to ensure consistency across comparable ini-
tiatives standardizing outcome reporting in RCT (Table II).
When considering the reporting of live birth, participants recom-
mended twin and higher multiple births should be reported as a single
live birth event (Table III). This will ensure treatments which increase
twin and higher multiple births are not favored. The participants agreed
that the summary effect size estimate and 95% CI should be calculated
for live birth events only, and recommended the number of participants
randomized as the most appropriate denominator. In addition to
reporting live birth events, singleton, twin and higher multiple births
should be reported narratively. When calculating the corresponding per-
centages for live birth events and singleton, twin and higher multiple
births, the number of participants randomized is the recommended
denominator.
Carefully selecting an appropriate denominator will avoid common
issues associated with the analyses of data arising from infertility trials,
particularly for studies related to ART. These issues are discussed in
detail within the discussion.
Viable intrauterine pregnancy confirmed by
ultrasound
Participants agreed a consensus definition, which included visualization
of a heartbeat. Participants discussed the reporting of twin and higher
multiple pregnancies and recommended they should be reported as a
single pregnancy event. The effect size estimate and 95% CI should be
calculated for pregnancy events only. Participants concluded that it
was also important for singleton, twin and higher multiple pregnancy
to be routinely reported. When calculating the corresponding percen-
tages for pregnancy events and singleton, twin and higher multiple
pregnancies, the number of participants randomized is the denomina-
tor which should be used.
Participants discussed the importance of embedding RCT within
routine clinical practice and were reluctant to insist upon mandatory
urinary or serum beta-hCG testing or ultrasonographic examinations in
addition to routine care. The variation in routine ultrasonographic ex-
amination between countries was discussed, for example, routine ul-
trasound scans are performed between 6 and 8 weeks in the USA,
between 11 and 13 weeks in the UK and following 16 weeks in the
Netherlands. Following the discussion, a contextual statement was rec-
ommended to ensure researchers consistently reported the gestation
at which the ultrasonographic examination diagnosing viable intrauter-
ine pregnancy was performed.
Pregnancy loss
Ectopic pregnancy
Following discussion, consensus was reached to adopt the ICMART
definition of ectopic pregnancy.
Miscarriage
Participants discussed the WHO’s definition for miscarriage and ob-
served this definition was the most widely used within an international
context. The definition includes a gestational age threshold of 20 com-
pleted weeks. They observed such a threshold would correlate well
with the IMPRINT statement’s definition of live birth, which was previ-
ously adopted. Participants unanimously agreed to modify the
ICMART definition of late fetal loss to include an estimated gestational
age threshold of 20 completed weeks. Within the context of this core
outcome set, participants recommended miscarriage should only be
reported after a viable pregnancy has been confirmed by ultrasound.
Stillbirth
Participants discussed the variety of contextual factors including local
cultural influences, legislative framework and national and international
reporting requirements, which would influence the different gestational
age thresholds incorporated in different definitions of stillbirth. They
.......................................................................................................
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Table II Standardized definitions for the core outcome set for infertility.
Viable intrauterine pregnancy
confirmed by ultrasound
A pregnancy diagnosed by ultrasonographic
examination of at least one fetus with a discernible
heartbeat.
• Researchers should report at which gestation the ultra-
sound examination was performed.
• Pregnancies are counted as pregnancy events, for ex-
ample, a twin pregnancy is counted as one pregnancy
event.
• Effect size estimates and 95% confidence interval
should be reported for pregnancy events. The denomi-
nator should be per participant randomized.
• Singleton, twin and higher multiple pregnancy should
be reported separately.
Pregnancy loss • When considering twin and higher multiple pregnan-
cies, pregnancy loss should be explicitly accounted for.
Ectopic pregnancy A pregnancy outside the uterine cavity, diagnosed by
ultrasound, surgical visualization or histopathology.
Miscarriage The spontaneous loss of an intrauterine pregnancy
prior to 20 completed weeks of gestational age.
• Miscarriage should be reported after a viable preg-
nancy has been confirmed by ultrasound.
Stillbirth The death of a fetus prior to the complete expulsion or
extraction from its mother after 20 completed weeks
of gestational age. The death is determined by the fact
that, after such separation, the fetus does not breathe
or show any other evidence of life, such as heartbeat,
umbilical cord pulsation or definite movement of volun-
tary muscles.
• When considering stillbirth involving twins and higher
multiple births they should be reported as a single
event.
Termination of pregnancy Intentional loss of an intrauterine pregnancy, through
intervention by medical, surgical or unspecified means.
• Selective embryo or fetal reduction should be
reported.
Live birth The complete expulsion or extraction from a woman
of a product of fertilization, after 20 completed weeks
of gestational age; which, after such separation,
breathes or shows any other evidence of life, such as
heart beat, umbilical cord pulsation or definite move-
ment of voluntary muscles, irrespective of whether the
umbilical cord has been cut or the placenta is attached.
A birth weight of 350 g or more can be used if gesta-
tional age is unknown.
• Live births are counted as birth events, for example,
twin live birth is counted as one live birth event.
• Effect size estimates and 95% confidence interval
should be reported for live birth events. The denomi-
nator should be per participant randomized.
• Singletons, twin and higher multiple births should be
reported separately.
Gestational age at birth The age of a fetus is calculated by the best obstetric
estimate determined by assessments which may include
early ultrasound, and the date of the last menstrual
period, and/or perinatal details. In the case of
assisted reproductive techniques, it is calculated by
adding 14 days to the number of completed weeks
since fertilization.
• The gestational age of both live births and stillbirths
should be reported.
• Gestational age at birth should be reported as a me-
dian and interquartile range. Reporting the mean and
standard deviation in addition would support future
meta-analysis.
Birthweight Birth weight should be collected within 24 h of birth
and assessed using a calibrated electronic scale with
10-g resolution.
• The birthweight of singletons, twins and higher multi-
ples should be reported separately.
• Birthweight for each newborn infant of the multiple
birth set should be reported.
• Birthweight should not be adjusted for gestational age.
• The birthweight of stillbirths should be reported.
Neonatal mortality Death of a live born baby within 28 days of birth. This
can be sub-divided into early neonatal mortality, if death
occurs in the first 7 days after birth and late neonatal,
if death occurs between 8 and 28 days after birth.
• Mortality related to preterm infants should be col-
lected up to 28 days beyond their estimated due date.
• If a member of a multiple birth set dies in the neonatal
period this should be explicitly reported.
Major congenital anomaly Structural, functional and genetic anomalies, that occur
during pregnancy, and identified antenatally, at birth, or
later in life, and require surgical repair of a defect, or
are visually evident, or are life-threatening, or cause
death.
• Major congenital anomalies should be classified using a
standardized taxonomy.
• Major congenital anomaly should be reported as an in-
fant with at least one major congenital anomaly
detected.
• If a major congenital anomaly is identified in a member
of a multiple set this should be explicitly reported.













































..highlighted the importance of accounting for all pregnancy losses and
the gestational age threshold for stillbirth would need to consider the
threshold already agreed for miscarriage. Participants unanimously
agreed to modify the ICMART definition to include a gestational age
threshold of 20 completed weeks with an appropriate adjustment for
birthweight. When considering stillbirth involving twins and higher mul-
tiple pregnancies, participants recommended they should be reported
as a single event.
Termination of pregnancy
Following discussion, consensus was reached to adopt the ICMART
definition of termination of pregnancy. Participants noted the impor-
tance of reporting selective embryo or fetal reduction.
Participants discussed the reporting of pregnancy loss and recom-
mended ectopic pregnancies, miscarriages, stillbirths and terminations
of pregnancy should be reported numerically. Percentages and effect
size estimates should not be reported. When considering twin and
higher multiple pregnancies, participants recommended pregnancy
losses should be accounted for within the footnotes of the reporting
table and summarized narratively within the study report.
Gestational age at delivery
Following discussion, consensus was reached to adopt the ICMART
definition of gestational age. Participants recommended that gestational
age at delivery should be reported for both live births and stillbirths.
Participants agreed gestational age at delivery should be reported as
the median and interquartile range. An effect size estimate should not
be reported. Participants recommended that researchers should be
encouraged to report the mean and SD within the reporting table
footnote to support future meta-analysis.
Birthweight
Participants noted the measurement of birthweight as being well-
characterized. Participants noted best practice recommendations,
which recommend collecting birthweight within 24 h of birth and using
a calibrated electronic scale with 10-g resolution. If there is limited
availability of correctly calibrated electronic scales, the type of scale
and its calibration should be clearly reported. Participants recom-
mended birthweight should not be adjusted for gestational age.
Participants agreed birthweight, reported as a mean and SD, should be
............................................................................................................................................................................................................................
Table III Generic reporting table.
Experimental Control Effect size
estimate (95% CI)*N N
Live birth event, no. (%)†
Singleton, no. (%)
Twin, no. (%)
Higher multiples, no. (%)
Viable pregnancy confirmed by ultrasound, no. (%)†
Singleton pregnancy, no. (%)
Twin pregnancy, no. (%)





Termination of pregnancy, no.
Gestational age at delivery (weeks of gestation), median (IQR)§
Birthweight
Singleton, g. (mean, SD)
Twin, g. (mean, SD)|
Higher multiples, g (mean, SD)|
Neonatal mortality, no.¶
Major congenital anomaly, no.#
*Effect size estimates and 95% CI should only be reported for live birth event and viable pregnancy confirmed by ultrasound. The remaining data should be summarized narratively.
†For live birth event and viable pregnancy confirmed by ultrasound the number of participants randomized should be used as the denominator.
‡When considering twin and higher multiple pregnancies, pregnancy loss should be explicitly accounted for within the table footnote.
§For gestational age at delivery reporting the mean and SD within the table footnote would support future meta-analysis.
|The birthweight for each newborn infant of the multiple birth set should be reported.
¶If a member of a multiple birth set dies in the neonatal period this should be explicitly stated within the table footnote.
#Reported as an infant with at least one major congenital anomaly detected. If a major congenital anomaly is identified in a member of a multiple set this should be explicitly stated
within the table footnote.
g, grams; N, number of randomized participants; No, number of events; IQR, interquartile range.




































































































recorded separately for singleton, twin and higher multiple infants. The
birthweight for each infant of a multiple birth set should be reported.
Neonatal mortality
Participants noted the consistent use of the WHO definition for neo-
natal mortality across definition development initiatives, including
ICMART, international and national guidelines and Cochrane system-
atic reviews. A contextual statement was agreed to ensure researchers
report any mortality of preterm infants up to 28 days beyond their es-
timated due date. Participants agreed neonatal mortality should be
reported numerically. Percentages and effect size estimates should not
be reported. If a member of a multiple birth set dies in the neonatal
period this should be stated within the reporting table footnote and
summarized narratively within the study report.
Major congenital anomaly
Participants discussed how congenital anomalies varied in severity,
with severe anomalies impacting upon an infant’s health, development
and survival. Participants reached a view that future RCT should con-
sistently report major congenital anomalies. Participants unanimously
agreed to modify the ICMART definition to include criteria to ensure
only major congenital anomalies are reported. Participants stated the
importance of classifying congenital anomalies using a standardized tax-
onomy (DeSilva et al., 2016). Participants agreed major congenital
anomalies should be reported as an infant with at least one major con-
genital anomaly detected. If a major congenital anomaly is identified in
a member of a multiple set this should be stated within the reporting
table footnote and summarized narratively within the study report.
Percentages and effect size estimates should not be reported.
Time to pregnancy leading to live birth
Detailed guidance regarding the collection, analysis and reporting of
time to pregnancy leading to live birth was approved by the meeting
participants and has been provided as Supplementary Data File S1.
Discussion
Definition development initiatives, clinical practice guidelines and
Cochrane reviews have defined individual core outcomes in different
ways. Through formal consensus methods, 14 healthcare professionals,
7 researchers and 6 people with fertility problems, from 11 countries,
have successfully developed consensus definitions for all core out-
comes. Specific recommendations have been made to improve the
reporting of core outcomes.
This study has used formal consensus methods to develop consen-
sus definitions for the core outcome set for infertility. The consensus
development conference is a formal consensus development method
developed by the US National Institutes of Health and has been used
to reach consensus on a variety of topics in many different countries
including, Canada, UK and Sweden. The study has engaged a range of
different stakeholders, including healthcare professionals, researchers
and people with fertility problems, from different countries. Such diver-
sity should secure the generalizability of the results and increase its
credibility with other researchers. The study has developed clear and
concise recommendations to enable future researchers to collect core
outcomes in a standardized approach and report their results in a clear
and transparent manner.
This study is not without limitations. There is significant uncertainty
regarding the optimal methods for core outcome set development
(Duffy and McManus, 2016; Williamson et al., 2017; Duffy et al.,
2019a). The COMET initiative has made no formal recommendations
regarding the development of consensus definitions. They advocate
the use of formal consensus development method in other aspects of
core outcome set development, which informed the methodological
choices we made in this study. Different formal consensus methods,
including the modified Delphi method and modified Nominal Group
Technique, could have been used. Further methodological research is
required to evaluate the most appropriate consensus methods for
studies similar to ours. Consideration should be given to the represen-
tativeness of the steering group and consensus meeting participants.
Many consensus meeting participants were from European countries
(n¼ 12; 44%) and there was limited representation from low- and
middle-income countries, which could have impacted upon the devel-
opment of consensus definitions. Further research should be under-
taken to evaluate virtual or blended formats to improve
representation while preserving limited resources.
Analyses of data arising from infertility trials, particularly for studies
related to ART, are frequently undermined by the use of an inappro-
priate denominator (Wilkinson et al., 2016). Two main issues exist.
The first is the use of a post-randomization denominator, for example,
when live birth rates are calculated per embryo transferred, rather
than per woman randomized. Analyses conducted on this basis do not
reflect the randomized comparisons, as the groups being compared
may differ with respect to their characteristics, and therefore, also
with respect to their outcomes (Hirji and Fagerland, 2009). The sec-
ond issue relates to analyses that commit a unit of analysis error (Vail
and Gardener, 2003). This error occurs when proportions are calcu-
lated using an inappropriate denominator, for example, the number of
oocytes or number of embryos. Unit of analysis errors commonly
occurs when researchers calculate the pregnancy rate by dividing the
number of gestational sacs on ultrasound by the number of embryos
transferred. As the outcomes of a couple’s embryos are correlated,
this approach is incorrect as standard statistical tests assume that the
tested observations are independent.
To avoid these important issues, it is good practice to calculate via-
ble pregnancy confirmed by ultrasound and live birth events using the
number of participants randomized as the denominator. This approach
is explicitly stated within the core outcome set recommendations.
Sophisticated statistical analysis methods capable of accommodating
post-randomization comparisons and clustered data do exist. They
could be reported in addition to the core outcome set if researchers
had access to the necessarily statistical expertise.
This study has developed the generic building blocks for future infer-
tility research. A minimum data set affords the opportunity for
researchers to easily populate protocols, case report forms and other
data collection tools with core outcomes and consensus definitions.
The generic reporting table should assist researchers to clearly report
their results within journal publications and conference presentations.
Implementing a standardized approach should reduce poor reporting
practices, for example, incomplete reporting, selective reporting based
on statistical significance and inappropriate use of denominators




































































































(Wilkinson et al., 2016). It is anticipated that research studies with
limited access to methodological and statistical advice will benefit
the most.
Systematic implementation of this core outcome set should ensure
the core outcomes are consistently defined by individual trials.
Symmetrical application of standardized definitions in all trial arms is
known to reduce measurement bias, including observer and verifica-
tion bias (Mansournia et al., 2017). Blinding outcome assessors to the
treatment allocation would further reduce bias (Sterne et al., 2016).
Outcome assessors should also undertake comprehensive training.
Other strategies can help to ensure consensus definitions are applied
correctly and, in a manner, which is unlikely to vary, including stan-
dardized data collection tools, internal validation studies and indepen-
dent adjudication panels. A freely available electronic case report form
and data repository are currently being planned to standardize the col-
lection of the core outcome set within future infertility trials
(COMMIT-Collection).
The Core Outcomes in Women’s and Newborn Health
(CROWN) initiative, supported by over 80 specialty journals, including
the Cochrane Gynaecology and Fertility Group, Fertility and Sterility and
Human Reproduction, have resolved to implement the core outcome
set for infertility (Core Outcomes in Women’s and Newborn Health
Initiative, 2014). In the future participating journals will request
researchers to report the definitions for individual core outcomes
within published trial reports. When the consensus definition has not
been used, the researchers will be asked to report this observation
and its implications for their findings. Reporting will be facilitated by
the recommendations made within this study.
The need to combine the results of individual trials evaluating fertility
treatments should be anticipated by researchers (Wilkinson et al.,
2019b). Implementing the core outcome set, including consensus defi-
nitions, should be considered good practice and could make a signifi-
cant contribution in improving the coordination, development and
delivery of fertility research within regional, national and international
settings (Devall et al., 2020). Standardization will facilitate pairwise
meta-analysis and more sophisticated secondary research, including
IPD and network meta-analysis (Duffy et al., 2019b). These
approaches could provide unique insights into the effectiveness and
safety of fertility treatments.
The consensus definitions developed as part of this study could be
incorporated into other core outcome sets to promote additional har-
mony across women’s health. Other core outcome sets have been
developed for endometriosis, hyperemesis gravidarum and preterm
birth, which share common core outcomes including live birth, neona-
tal mortality and major congenital anomalies (van ’t Hooft et al., 2016;
Jansen et al., 2020; Duffy et al., 2020b). Core outcome set developers
should be encouraged to use the consensus definitions developed as
part of this study.
Standardized consensus definitions are not meant to limit regional,
national and international requirements to collect and report collect
core outcomes using specific definitions, including live birth, stillbirth
and congenital anomalies. For example, researchers undertaking re-
search in the UK may wish to define stillbirth as occurring after
22 weeks of gestation, in line with national recommendations (Da Silva
et al., 2016). Researchers wishing to collect data using other definitions
in the context of their own RCT would continue to be able to do so.
Selective reporting should be avoided by presenting findings for both
the consensus definition and any other definition used. Researchers
would need to carefully consider how these data would be collected
to fulfill different definitions and reporting obligations.
The ultimate objective of an infertility trial is a healthy baby who
develops normally. There are significant challenges in developing an
objective consensus definition regarding what constitutes a ‘healthy
baby’ as contextual factors, including local practices, cultural influences
and legal implications, are important considerations. Consensus was
reached to define live birth based on a 20-week gestational age thresh-
old, reflecting IMPRINT recommendations and WHO guidelines. The
current limit of viability is considered to be 22 weeks of gestation;
however, the threshold is constantly challenged as perinatal and neo-
natal medicine advances. This context was also considered and a clear
threshold has been decided through a robust consensus process to fa-
cilitate clear reporting across future infertility research (The Harbin
Consensus Conference Workshop Group, 2014).
The core outcome set should be reported by all future RCTs evalu-
ating potential fertility treatments. This context is important when con-
sidering the consensus definition developed for pregnancy and
miscarriage. Routine urinary or serum beta-hCG testing is a common
feature of IVF research, however, is less likely when evaluating other
interventions. To take this into account, the consensus definition for
pregnancy and miscarriage includes ultrasound, which is a common
component of antenatal care. An extension to the core outcome set
specifically for IVF research (COMMIT-IVF) is currently being devel-
oped and includes pregnancy confirmed by urinary or serum beta-
hCG testing and early miscarriage.
The development of consensus definitions has provided additional
focus upon the language researchers commonly use when reporting in-
fertility research. People with fertility problems and the patient organi-
zations involved in this study have routinely commented upon
terminology. It has been often perceived as lacking a patient-centric
approach including terms such as missed spontaneous abortion, in-
duced abortion and fetal loss. Researchers should recognize the lan-
guage used to report fertility research is important and holds
significance to people with fertility problems. The standardization of
terminology within this core outcome set has been developed to en-
sure precision and with consideration to good practice guidelines in
partnership with people with fertility problems and the patient
organizations.
The COMMIT initiative has committed to undertaking further re-
search to assess the uptake and implementation of the core outcome
set for infertility (COMMIT-Implementation). Assessing the uptake of
the core outcome set, including the use of consensus definitions, will
be undertaken by examining registry records, published protocols and
RCT. Further research is planned to examine and understand the rea-
sons why researchers do, and do not, implement the core outcome
set for infertility. By identifying perceived barriers to implementation,
strategies will be developed to promote implementation of the core
outcome set across future infertility research.
In conclusion, ensuring that core outcomes are consistently defined
across RCT evaluating potential fertility treatments will secure evi-
dence which is more accessible and facilitate the translation of re-
search into clinical practice. Standardized reporting should help limit
poor reporting practices. Future researchers should benefit from core
outcomes and consensus definitions, which can be included in proto-
cols, case report forms and other data collection tools. The generic




































































































reporting table should assist researchers in clearly reporting their
results in journal publications and conference presentations.
Supplementary data
Supplementary data are available at Human Reproduction online.
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